A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Official record

Identifier

NCT07229313

Recruiting locations

countries

United StatesAustralia

Interventions studied

KIVU-107

Lead sponsor

Kivu Bioscience Inc.

Target enrolment

76 participants

Study type

INTERVENTIONAL

Phase

Phase 1

Status

Recruiting

First posted

Nov 14, 2025

Last updated on the registry

Sep 24, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Male or female ≥18 years of age
* No therapy of proven efficacy exists for the tumor
* Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available.
* Adequate bone marrow, kidney, and liver function
* Measurable disease using RECIST v1.1
* ECOG 0 or 1
* Life expectancy ≥ 3 months

Exclusion Criteria:

* Prior treatment with any ADC with topoisomerase 1 inhibitor payload
* Any PTK7 - targeted therapy
* Uncontrolled cardiovascular disease
* Active Hepatitis B, Hepatitis C, or HIV infection
* History of interstitial lung disease
* Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.

Indexed under

Esophageal Cancer